Literature DB >> 26711228

Cepharanthine alleviates liver injury in a rodent model of limb ischemia-reperfusion.

Yin-Kuang Chang1, Su-Cheng Huang1, Ming-Chang Kao2, Chun-Jen Huang3.   

Abstract

OBJECTIVES: Limb ischemia-reperfusion (I/R) causes remote organ injury (e.g., liver injury). Oxidation and inflammation are crucial mechanisms. We investigated the effects of cepharanthine, a potent antioxidative and anti-inflammatory drug, on alleviating liver injury induced by limb I/R.
METHODS: Twenty-four adult male Sprague-Dawley rats were randomized to receive sham operation (Sham), Sham plus cepharanthine, I/R, or I/R plus cepharanthine and designated as the Sham, Sham+Cep, I/R, or I/R+Cep group, respectively (n = 6 in each group). I/R was induced by applying rubber band tourniquets high around each hind limb for 3 hours followed by reperfusion for 24 hours.
RESULTS: The plasma levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) of the Sham and Sham+Cep groups were low, and the levels of AST and ALT of the I/R group were significantly higher than those of the Sham group (both p<0.001). By contrast, the AST and ALT of the I/R+Cep group were significantly lower than those of the I/R group (both p<0.001). The hepatic levels of nitric oxide (NO), malondialdehyde (MDA), macrophage inflammatory protein 2 (MIP-2), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) of the Sham and Sham+Cep groups were also low. As expected, the NO, MDA, MIP-2, IL-6, and COX-2/PGE2 of the I/R group were significantly higher than those of the Sham group (all p<0.001). By contrast, the NO, MDA, MIP-2, IL-6, and COX-2/PGE2 of the I/R+Cep group were significantly lower than those of the I/R group (all p<0.05).
CONCLUSION: Cepharanthine alleviates liver injury in a rodent model of limb I/R. The mechanisms may involve reducing oxidation and inflammation.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  COX-2; chemokine; cytokine; inflammation; oxidation; prostaglandin

Mesh:

Substances:

Year:  2015        PMID: 26711228     DOI: 10.1016/j.aat.2015.11.004

Source DB:  PubMed          Journal:  Acta Anaesthesiol Taiwan


  6 in total

1.  Bioavailability Enhancement of Cepharanthine via Pulmonary Administration in Rats and Its Therapeutic Potential for Pulmonary Fibrosis Associated with COVID-19 Infection.

Authors:  Jian Li; Guangrui Chen; Zhiyun Meng; Zhuona Wu; Hui Gan; Xiaoxia Zhu; Peng Han; Taoyun Liu; Fanjun Wang; Ruolan Gu; Guifang Dou
Journal:  Molecules       Date:  2022-04-24       Impact factor: 4.927

2.  Effects of hyperbaric therapy on liver morphofunctional of rabbits (Oryctolagus cuniculus) after hind limb ischemia-reperfusion injury.

Authors:  Bambang Sektiari Lukiswanto; Wiwik Misaco Yuniarti; Y Yosis Motulo
Journal:  Vet World       Date:  2017-11-14

3.  Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model.

Authors:  Eliza W Beal; Curtis Dumond; Jung-Lye Kim; Khalid Mumtaz; Don Hayes; Ken Washburn; Bryan A Whitson; Sylvester M Black
Journal:  J Vis Exp       Date:  2017-04-02       Impact factor: 1.355

Review 4.  Cepharanthine: An update of its mode of action, pharmacological properties and medical applications.

Authors:  Christian Bailly
Journal:  Phytomedicine       Date:  2019-05-10       Impact factor: 5.340

5.  Cepharanthine Attenuates Early Brain Injury after Subarachnoid Hemorrhage in Mice via Inhibiting 15-Lipoxygenase-1-Mediated Microglia and Endothelial Cell Ferroptosis.

Authors:  Shiqi Gao; Liuzhi Zhou; Jianan Lu; Yuanjian Fang; Haijian Wu; Weilin Xu; Yuanbo Pan; Junjie Wang; Xiaoyu Wang; Jianmin Zhang; Anwen Shao
Journal:  Oxid Med Cell Longev       Date:  2022-02-09       Impact factor: 6.543

6.  How important is the damage to the liver after lower limb ischemia-reperfusion? An experimental study in a rat model.

Authors:  Gamze Gökalp; Bortecin Eygi; Müge Kiray; Burcu Açıkgöz; Emel Berksoy; Yüksel Bıcılıoğlu; Neslihan Zengin; Şahin İşcan; Orhan Gökalp; Ali Gürbüz
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-01-23       Impact factor: 0.332

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.